Dyne Therapeutics Announces Chief Scientific Officer Transition
June 02 2021 - 4:05PM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases, today announced
that Romesh Subramanian, Ph.D. has chosen to step down as chief
scientific officer for personal reasons and will continue to serve
as an advisor to Dyne. Concurrently, Oxana Beskrovnaya, Ph.D., who
has served as Dyne’s senior vice president, head of research since
January 2020, has been appointed CSO.
“In co-founding Dyne, Romesh laid the foundation of our efforts
to advance modern oligonucleotide therapies that can be effectively
delivered to muscle and ultimately transform the lives of people
living with serious genetically driven diseases. We are grateful
for his many contributions that have helped us build our pipeline,
now on the cusp of entering the clinic, and are pleased that he
will remain a part of the Dyne family as an advisor,” said Joshua
Brumm, Dyne’s president and chief executive officer. “I’m very
excited to have Oxana step into her new role and build on the
impressive work she’s led since joining us early last year. She has
been instrumental in enhancing our scientific expertise, attracting
top talent to our research team and progressing our programs for
patients in need.”
“It has been a great privilege to be part of Dyne and to have
accomplished significant milestones – from designing our innovative
FORCE™ platform, to generating validating preclinical data, and to
now be driving three promising programs toward the clinic,” said
Dr. Subramanian. “For my family and me, this is the right time to
step down as CSO of Dyne, and I am pleased that Oxana is
well-positioned to take our programs forward. Dyne has an exciting
platform and a very strong team in place. I look forward to seeing
our continued progress and supporting the company in any way that I
can.”
Prior to joining Dyne, Dr. Beskrovnaya served as head of
musculoskeletal and renal research in Sanofi’s rare disease and
neurological unit, advancing a pipeline of drug candidates using
multiple therapeutic modalities, including nucleic acids, proteins
and small molecules. She is the author of numerous patents, invited
reviews, editorials, book chapters and original research articles
in major scientific journals. Dr. Beskrovnaya received her Ph.D. in
genetics from Moscow Genetics Institute, followed by postdoctoral
fellowship training in neuromuscular diseases at the Howard Hughes
Medical Institute at the University of Iowa.
“I joined Dyne because of the tremendous opportunity we have to
build the world’s leading muscle disease company. I’m honored to
lead this team and continue the important work ahead of us to
deliver new therapeutic options for patients,” said Dr.
Beskrovnaya.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company
dedicated to advancing innovative life-transforming therapeutics
for people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue seen with other
approaches. Dyne’s broad portfolio of therapeutic candidates
for serious muscle diseases includes programs for
myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy
(DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more
information, please visit https://www.dyne-tx.com/, and follow
us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, contained in this press
release, including statements regarding Dyne’s strategy, future
operations, prospects, plans, objectives of management, the
submission of investigational new drug applications and
commencement of clinical development and the sufficiency of its
cash resources, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,”
“predict,” “project,” “potential,” “should,” or “would,” or the
negative of these terms, or other comparable terminology are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Dyne
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various important factors, including:
uncertainties inherent in the identification and development of
product candidates, including the conduct of research activities
and the initiation and completion of preclinical studies and
clinical trials; uncertainties as to the availability and timing of
results from preclinical studies and clinical trials; the timing of
and Dyne’s ability to submit investigational new drug applications;
whether results from preclinical studies will be predictive of the
results of later preclinical studies and clinical trials;
uncertainties related to Dyne’s ability to obtain sufficient cash
resources to fund the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements for the
anticipated periods; the impact of the COVID-19 pandemic on Dyne’s
business and operations; as well as the risks and uncertainties
identified in Dyne’s filings with the Securities and Exchange
Commission (SEC), including the Company’s most recent Form 10-Q and
in subsequent filings Dyne may make with the SEC. In addition, the
forward-looking statements included in this press release represent
Dyne’s views as of the date of this press release. Dyne anticipates
that subsequent events and developments will cause its views to
change. However, while Dyne may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Dyne’s views as of any date subsequent to the date of
this press release.
Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024